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Abstract  
 
Aberrant expression of the sodium channel gene (SCN5A) has been proposed to disrupt 
cardiac action potential and cause human cardiac arrhythmias, but the mechanisms of 
SCN5A gene regulation and dysregulation still remain largely unexplored. To gain insight 
into the transcriptional regulatory networks of SCN5A, we surveyed the promoter and first 
intronic regions of the SCN5A gene, predicting the presence of several binding sites for 
GATA transcription factors (TFs). Consistent with this prediction, chromatin 
immunoprecipitation (ChIP) and sequential ChIP (Re-ChIP) assays show co-occupancy of 
cardiac GATA TFs GATA4 and GATA5 on promoter and intron 1 SCN5A regions in fresh-
frozen human left ventricle samples. Gene reporter experiments show GATA4 and GATA5 
synergism in the activation of the SCN5A promoter, and its dependence on predicted GATA 
binding sites. GATA4 and GATA6 mRNAs are robustly expressed in fresh-frozen human left 
ventricle samples as measured by highly sensitive droplet digital PCR (ddPCR). GATA5 
mRNA is marginally but still clearly detected in the same samples. Importantly, GATA4 
mRNA levels are strongly and positively correlated with SCN5A transcript levels in the 
human heart. Together, our findings uncover a novel mechanism of GATA TFs in the 
regulation of the SCN5A gene in human heart tissue. Our studies suggest that GATA5 but 
especially GATA4 are main contributors to SCN5A gene expression, thus providing a new 
paradigm of SCN5A expression regulation that may shed new light into the understanding of 
cardiac disease.  
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Chromatin immunoprecipitation: ChIP 
Complementary RNA: cRNA 
Droplet digital PCR: ddPCR 
GATA binding sites: GATA-BS 
Human embryonic kidney: HEK 
Sequential ChIP: Re-ChIP 
Sodium channel, voltage-gated, type V alpha subunit: NaV1.5 
Transcription start site: TSS 
Transcription factor: TF 
Wild-Type: WT 
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1. Introduction  
 
Sodium channel, voltage-gated, type V alpha subunit (NaV1.5) drives the sodium current that 
initiates the upstroke of the cardiac action potential [1]. NaV1.5 interacts with several 
regulatory proteins (β-subunits, Nedd4-2 ubiquitin ligase, calmodulin, among others) that 
modulate NaV1.5 membrane trafficking and function [2]. Genetic mutations in the SCN5A 
gene, which encodes the NaV1.5 subunit, have been linked to cardiac arrhythmias (Brugada 
syndrome, long QT syndrome type 3, idiopathic ventricular fibrillation, atrial fibrillation, 
progressive cardiac conduction defects, congenital sick sinus syndrome, and sudden infant 
death syndrome) [1, 3].  
However, recent findings also suggest that aberrant SCN5A gene expression may increase 
susceptibility to arrhythmogenic diseases. For example, low NaV1.5 levels in heterozygous 
Scn5a +/- knockout mice recapitulate cardiac defects found in human individuals carrying 
disease-associated SCN5A mutations, and the severity of these defects is directly correlated 
with levels of NaV1.5 expression [4]. In addition, certain haplotypes in the SCN5A promoter 
have been associated with aberrant SCN5A promoter activity and QRS duration on the 
electrocardiogram [5]. Finally, a common genetic variant (rs6801957) found in a distal 
SCN5A enhancer region has been associated with abnormal SCN5A expression and slow 
cardiac conductance [6, 7]. The rs6801957 variant impairs T-box transcription factor 3 and 5 
(TBX3/TBX5) binding to the enhancer, and has been proposed to promote changes in 
SCN5A expression. Collectively, these few studies suggest that dysregulation of SCN5A 
gene expression may be linked to cardiac disease, and that understanding the mechanisms 
of SCN5A transcriptional regulation may uncover novel determinants of sodium channel-
related cardiac diseases.  
 
The core promoter of the human SCN5A gene spans from nucleotides -261 to +140 relative 
to the transcription start site (TSS, +1) [8], and it contains conserved regions with putative 
regulatory functions. Downstream conserved regions may also contain potential cis-
regulatory elements, between TSS and exon 1 and within intron 1 [9]. In particular, intron 1 
contains a predicted GATA1 binding site (BS). Mutation of this site reduces the promoter 
activity of the Scn5a gene in neonatal mouse cardiomyocytes, suggesting a direct role of 
GATA TFs in the regulation of basal SCN5A transcription [8]. The mammalian genome 
encodes six GATA TFs (GATA1-6). From those, GATA4, GATA5 and GATA6 are expressed 
in mesoderm- and endoderm-derived tissues, including the heart. [10]. GATA-BS are 
present in cis-regulatory regions of multiple cardiac-specific genes and are required for their 
proper cardiac expression [11]. GATA4 is considered a master regulator of cardiac 
transcriptional networks, and plays a key role in cardiogenesis and in adult cardiac cells [12]. 
Mechanistically, GATA4 acts synergistically with other TFs and activates gene expression by 
promoting H3K27ac deposition [13]. Of note, GATA4 has been described to be involved in 
the developing atrioventricular cardiac conduction system; accordingly, heterozygous Gata4 
+/- mice display short PR intervals [14]. Mutations in the GATA4 gene affecting DNA binding 
or interactions to other TFs have also been linked to heart dysfunction [15, 16].  
 
Here, we explored a potential role of GATA TFs on transcriptional regulation of the human 
SCN5A gene. We found that cardiac GATA TFs, mainly GATA4 and also GATA5, regulate 
the expression of the SCN5A gene via a synergistic mechanism. In fresh-frozen human 
heart samples, we observed that GATA4 transcript levels positively correlate with SCN5A 
transcript levels. Overall, we suggest that GATA4 plays a major role in the regulation of the 
SCN5A gene in the human heart, which may shed new light into the understanding of 
human cardiac arrhythmias. 
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2. Materials and Methods  
 
2.1. Cells, Antibodies and Primers 
 
Cardiac cells derived from embryonic rat ventricle (H9c2 cells) and human embryonic kidney 
293 (HEK293) cells were maintained under standard cell culture conditions. Antibodies used 
in the experiments were: α-GATA4 (sc-1237x), α-GATA5 (sc-9054x), α-GATA6 (sc-7244x) 
(all from Santa Cruz Biotechnology, Dallas, TX, USA), α-HA (ab1424, Abcam, Cambridge, 
UK), α-actin (A2066, Sigma, St Louis, MO, USA), and α-FLAG (F1804, Sigma). Secondary 
HRP antibodies were: α-rabbit (32460), α-goat (31402), and α-mouse (32430) (all from 
Thermo Scientific, Rockford, IL, USA). 
For qPCR gene expression analyses, we used the following rat primers: Gata4 
(QT02350684) and Scn5a (QT00186263) from Qiagen (Hilden, Germany); Nppa 
(R_Nppa_1) and Kcnh2 (R_Kcnh2_1) from Sigma; β-actin (Fw 
5'AGCCATGTACGTAGCCATCC', Rv 5'CTCTCAGCTGTGGTGGTGAA3'). For droplet 
digital PCR (ddPCR) analyses, we used the following validated expression probes: GATA4-
FAM (dHsaCPE5050488), GATA5-FAM (dHsaCPE5036300), GATA6-FAM 
(dHsaCPE5037510), GATA4-HEX (dHsaCPE5050489), and GADPH-HEX 
(dHsaCPE5031597) from Bio-Rad. 
 
2.2. Plasmids and Site Directed Mutagenesis 
 
Details for plasmids and site directed mutagenesis are provided in Supplementary Materials 
and Methods.  
 
2.3. Computational Analyses  
 
TFSEARCH and MEME bioinformatic tools were used to identify GATA-BS in the SCN5A 
proximal promoter (from positions - 1125 bp to +857 bp from the TSS). 
 
2.4. Human Cardiac Tissue Collection 
 
Human left ventricle samples were collected from fourteen end-stage heart failure patients 
undergoing cardiac transplantation (Hospital Clínic, Barcelona). Control left ventricle heart 
samples, not used for transplantation, were obtained from four organ donors (Hospital Clínic, 
Barcelona). All individuals signed a written consent to participate in the study. Biopsies were 
collected from the explanted heart, washed and snap-frozen in liquid nitrogen immediately 
after surgery. To ensure minimum variation due to sample collection, all samples were 
dissected from the same heart area, the anterior wall of the left ventricle, by the same 
person. Histologically, samples comprise the three heart layers (epicardium, myocardium 
and endocardium). All procedures were approved by the ethical committees of the Hospital 
Dr. Josep Trueta de Girona and the Hospital Clínic de Barcelona and conform the principles 
outlined in the Declaration of Helsinki.  
 
2.5. Chromatin Immunoprecipitation (ChIP) and Sequential Chromatin 
Immunoprecipitation (Re-ChIP) Assays 
 
ChIP and Re-ChIP assays were performed using human adult left ventricle samples. ChIP 
was adapted from Gomes et al, 2006 [17] and Re-ChIP from Furlan-Magaril et al, 2009 [18]. 
An expanded description of these techniques is available in Supplementary Materials and 
Methods. 
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2.6. Transient Transfection and Luciferase Assays 
 
PromoterA-luciferase or PromoterB-luciferase (200 ng), EF1αPromoter-Renilla (20 ng) 
constructs, and GATA expression vectors were transfected into H9c2 cells using 
Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) following the 
manufacturer’s specifications. We transfected 1200 ng of each GATA expression vectors, 
except for the dose-response experiment in which we used 600, 1200 and 1800 ng. DNA for 
each condition was equalized with pcDNA3.1. Cells were harvested 48 hours later with 
passive lysis buffer (Promega, Madison, Wi, USA), and processed for firefly and renilla 
luciferase activity with Dual Luciferase Reporter Assay System on a GloMax-96 luminometer 
(Promega).  
 
2.7. RNAi Experiments 
 
We transfected H9c2 cells with 25 nM of ON-TARGETplus Non-targeting Pool (D-001810-
10) or two different siGENOME siRNA Rat Gata4 (D-090725-02 and D-090725-03; all from 
Dharmacon, Thermo Scientific) using Dharmaphect (Thermo Scientific). Forty-eight hours 
post-transfection, we isolated total RNA using the RNeasy Mini Kit (Qiagen) and treated the 
samples with DNase I to remove genomic DNA contamination. After reverse transcription of 
1 µg of RNA (Reverse Transcription kit, Qiagen) we performed qPCR with validated primers 
for the target genes (Gata4, Scn5a, Nppa, Kcnh2, and β-Actin) and the Kapa-SYBR Green 
detection (Kapa Biosystems, Wilmington, MA, USA) on a Mastercycler ep realplex 
(Eppendorf, Hauppauge, NY, USA). 
For the luciferase experiments, H9c2 cells were transfected with 25 nM of control or Gata4 
siRNAs and re-transfected after 24 hours with PromoterA-luciferase or PromoterB-luciferase 
(200 ng) and EF1αPromoter-Renilla (20 ng) constructs. Cells were harvested 24 hours later 
and processed for luciferase assay as described above. 
 
2.8. Co-immunoprecipitation Experiments 
 
We co-transfected HEK293 cells with HA/GATA4 (5 µg) and GATA5 (5 µg) expression 
vectors using Lipofectamine 2000. Forty-eight hours after transfection we lysed the cells in 
IP lysis buffer (50 mmol/L Tris HCl pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% NP-40 
and Protease Inhibitors Cocktail (PI; Roche, Madrid, Spain)) and incubated 1 mg of the total 
lysate with α-HA antibody. The immunocomplexes were subjected to Western blot with α-
GATA5 antibody. 1% of total protein was used as input.  
 
2.9. Sodium Current Recordings  
 
Xenopus laevis oocytes were obtained as described in the Supplementary Materials and 
Methods section. In vitro transcription of SCN5A gene was done using the mMESSAGE 
mMACHINE® T7 Transcription Kit (Life Technologies). Synthetic transcript (cRNA) 
concentration was determined using a NanoDrop spectrophotometer and checked by 
agarose gel electrophoresis. Different SCN5A cRNA dilutions were injected in Xenopus 
laevis oocytes and after 3 days at 18 ºC, four batches of oocytes were tested. We measured 
sodium currents by whole cell patch-clamp technique using two-microelectrode voltage 
clamp.  Peak current was determined at -20 mV and the holding potential was at -120 mV. 
Measurements were performed using reduced extracellular Na+ (20 mM). 
 
2.10. Gene Expression Analysis in Human Heart Tissue by Droplet Digital PCR  
 
We disrupted 30 mg of human left ventricle samples with a glass dounce homogenizer in 
RLT buffer (Qiagen), and purified the total RNA using the RNeasy Fibrous Tissue Mini Kit 
(Qiagen) according to the manufacturer’s instructions. To avoid contamination with genomic 
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DNA we included a step of DNase I treatment. Reverse transcription was performed as 
described above.  
Quantification by ddPCR was carried out in 20 µL reactions containing 1x ddPCR Supermix 
for Probes (No dUTP), 250 nM of each commercial probe, 900 nM specific commercial 
primers, and 1 µL or diluted cDNA according to manufacturer’s recommendations (PCR 
conditions: 10 min at 95°C, 40 cycles of 30 sec at 94°C and 30 sec at 55°C, and 10 min at 
98°C). Droplet generation and absolute droplet quantification was performed in a QX200 
Droplet Digital PCR System (Bio-Rad) using the QuantaSoft Software (Bio-Rad), and 
analysis was performed using Excel (Microsoft) and Prism (GraphPad). Quantification 
references: human GAPDH-HEX and GATA4-HEX. 
 
2.11. Statistical Analyses 
 
Data are reported as mean ± SEM. Statistical analysis was conducted with SPSS or 
GraphPad Prism 6 version for Mac (GraphPad). For two-groups-only comparisons, we 
conducted two-tailed t-test. For analysis of multiple groups, we conducted one-way ANOVA, 
multiple comparisons comparing the mean of each group to the mean of every other group. 
Differences were considered significant at p≤0.05: p≤0.05 (*), p≤0.01 (**), and p≤0.001 (***). 
 
 
3. Results  
 
3.1. GATA4 and GATA5 Co-Occupy the SCN5A Proximal Promoter in Human Heart 
 
To explore the potential role of GATA TFs in the regulation of the human SCN5A gene, we 
surveyed the SCN5A promoter for the presence of GATA-BS in the region comprised 
between -1125 and +857 bp of the SCN5A gene (hereafter referred to as SCN5A proximal 
promoter; +1 referring to the TSS). This in silico analysis predicted multiple GATA-BS in the 
SCN5A promoter and intron 1 (Supplementary Figure S1).  
 
Cardiac TFs GATA4, GATA5 and GATA6 are 85% identical in their amino acid sequence 
within the DNA binding domain, thus the three bind virtually to the same predicted GATA-BS 
[10]. We examined the binding of GATA4, GATA5 and GATA6 across the SCN5A promoter 
and first intronic regions in fresh-frozen human heart samples by ChIP analysis. Soluble 
chromatin of human adult left ventricles was prepared and incubated with GATA4, GATA5 or 
GATA6 antibodies (Figure 1A). In agreement with our computational prediction, qPCR 
analysis of the immunoprecipitated material showed robust binding of GATA4 and GATA5 
near to the TSS (-198 bp) and intron 1 (+505 bp) regions of the SCN5A gene. We did not 
detect binding of these TFs to the distal regions analyzed (-8803 and -5916 bp), which did 
not contain predicted GATA-BS. We observed some level of GATA6 binding on the same 
regions as GATA4 and GATA5, but ChIP enrichment was not statistically significant relative 
to control (Figure 1A). 
 
To examine whether GATA4 and GATA5 co-occupy the same DNA molecules of the SCN5A 
promoter or whether instead both occupy different DNA molecules, we next performed Re-
ChIP analyses in fresh-frozen human heart samples. Soluble chromatin fragments of the 
SCN5A gene first immunoprecipitated with GATA4 antibodies were efficiently re-
immunoprecipitated with GATA5 antibodies (Figure 1B). These results suggest that GATA4 
and GATA5 bind to the same DNA molecules of the SCN5A promoter and intron 1 regions. 
In support of our ChIP analysis, GATA6 did not show significant co-enrichment (Figure 1B). 
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Figure 1. GATA4 and GATA5 bind to the SCN5A proximal promoter in the human heart. A. ChIP 
assays from human left ventricle samples using antibodies against GATA4, GATA5 and GATA6, 
followed by qPCR. Numbers indicate central base pairs of amplicons. Results are shown as 
percentage of input (mean ± SEM, n=6). Significance was examined by the t-test relative to negative 
control (-8803 bp) region. B. Re-ChIP assays from human left ventricle samples. Chromatin was 
incubated with α-GATA4 antibody, and then immunocomplexes were subjected to a second round of 
immunoprecipitation using antibodies against GATA4, GATA5, GATA6 or without antibody (control). 
Results are shown as fold immunoprecipitated DNA relative to the control condition (mean ± SEM, 
n=6). Significance was examined by the t-test relative to no antibody control. *p≤0.05, **p≤0.01, and 
***p≤0.001. 
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3.2. GATA TFs Regulate SCN5A Gene Transcription 
 
To evaluate the functional relevance of GATA TF binding to the SCN5A promoter and intron 
1 regions, we next performed reporter assays in rat cardiac H9c2 cells. These cells derive 
from rat embryonic ventricle, and are a well-established “cardiac-like” cellular model to study 
gene expression [19]. We first examined whether endogenous rat GATA4 regulates rat 
Scn5a expression. Efficient RNAi-based Gata4 knockdown (80-90%) with two independent 
siRNAs induced 40-50% reduction in rat Scn5a mRNA expression (Figure 2A; decrease of 
GATA4 protein levels in Gata4-siRNA transfected cells shown in Supplementary Figure S2). 
As expected, mRNA levels of atrial natriuretic factor (Nppa), a well-known GATA4 target [20] 
[21], were similarly reduced upon Gata4 siRNA transfection, but we did not observe the 
same effect on mRNA expression of the non-GATA4 target Kcnh2 gene, which encodes a 
potassium channel involved in the repolarization phase of the cardiac action potential. These 
results support the specificity of our findings, and suggest that GATA4 positively regulates 
SCN5A gene expression. 
 
Next, we determined whether GATA TF regulatory effects on the SCN5A gene occur via 
binding to the promoter and first intronic regions, as suggested by the ChIPs assays in 
human cardiac tissue. We performed reporter assays using a PromoterA-luciferase 
construct, containing the luciferase gene under control of the fragment -713 to +282 bp 
(relative to the TSS) of the human SCN5A gene. We transfected H9c2 cells with the 
PromoterA-luciferase construct and increasing amounts of GATA4, GATA5 or GATA6 
expression vectors (analysis by Western blot confirmed correct expression of these three 
proteins; Figure 2B, right panel). GATA4 stimulated SCN5A promoter activity in a dose-
dependent manner (Figure 2B, left panel). GATA5 also stimulated SCN5A promoter activity, 
although to a lesser extent than GATA4. GATA6 overexpression led to marginal, but still 
significant activation at high concentrations. To exclude the possibility that overexpressed 
GATA6 was not fully transcriptionally active, we also tested the effect of GATA6 
overexpression on the pancreatic and duodenal homeobox 1 (Pdx1) promoter, a known 
target for both GATA4 and GATA6 [22]. We observed that GATA6 overexpression activates 
the reporter gene through the Pdx1 promoter (Supplementary Figure S3). 
 
GATA4 and GATA6 synergistically activate the natriuretic peptide Nppa and Nppb genes 
[20], as well as the pancreatic Pdx1 gene [22]. To test for GATA TF synergies in the control 
of the SCN5A gene, we co-transfected different combinations of GATA4, GATA5 and 
GATA6 expression vectors in H9c2 cells. We observed a synergistic effect on expression of 
the reporter gene when GATA4 and GATA5 were co-transfected (Figure 2C). However, we 
did not see evidence of synergistic effects upon co-transfection of GATA4 and GATA6, or 
GATA5 and GATA6. Notably, when GATA4 and GATA6 were co-transfected we detected a 
similar level of activation to the observed after overexpression of GATA4 alone. In a parallel 
experiment, we tested the effect of GATA4 and GATA6 co-expression on the Pdx1 promoter. 
In this case, we observed synergistic activation of GATA4 and GATA6, as previously 
reported [22] (Supplementary Figure S3). Altogether, these results suggest a major role of 
GATA4/5 synergism in the activation of the SCN5A promoter.  
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Figure 2. GATA TFs activate the SCN5A promoter. A. Gata4 siRNAs downregulate Scn5a 
expression. qPCR analysis of Gata4, Scn5a, Nppa and Kcnh2 mRNA levels from H9c2 cells 
transfected with control or Gata4 siRNAs (1 and 2). Transcript levels were normalized to β-Actin 
mRNA and reported as percentage relative to control siRNA (mean ± SEM, n=8). Significance was 
examined by the t-test relative to control siRNA. B. Left panel. Luciferase experiments in H9c2 cells 
transfected with PromoterA-luciferase construct and increasing amounts (600, 1200 and 1800 ng) of 
the indicated GATA TF expression vectors. Luciferase values were normalized to renilla and are 
shown as fold induction relative to non-overexpressing control conditions (mean ± SEM, n=6). 
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Significance was examined by the t-test relative to control. Right panel. Western blot of transfected 
samples shows correct expression of GATA TFs. C. Luciferase experiments in H9c2 cells transfected 
with PromoterA-luciferase and the indicated GATA factor (1200 ng). Luciferase values were 
normalized with renilla and are shown as fold induction relative to control (mean ± SEM, n=6). Multiple 
group comparison was performed using the ANOVA test. Statistical significance of SCN5A promoter 
activity in the presence of each GATA TF relative to control conditions is not shown in Figure 2C for 
clarity, and was as indicated in Figure 2B. *p≤0.05, **p≤0.01, and ***p≤0.001. 
 
 
3.3. GATA4/GATA5 Synergism Is Decreased In Mutated Intron 1 GATA-BS  
 
Our ChIP and Re-ChIP experiments show that, in addition to the region upstream TSS, 
GATA TFs also bind to the intronic 1 region (+505 bp). We therefore tested the effects of 
GATA TFs on a second construct, PromoterB-luciferase, that contains the luciferase gene 
under control of the fragment -260 to +612 bp from the SCN5A gene (Supplementary Figure 
S1). PromoterB showed 3-fold higher transcriptional activity on the reporter gene than 
PromoterA (Figure 3A), which supported previous findings suggesting that intron 1 contains 
additional cis-positive regulatory elements [8]. In addition, GATA4/5 synergism was greater 
on PromoterB than on PromoterA (Supplementary Figure S4), but we observed a similar 
(~40-60%) reduction in SCN5A promoter activity associated to Gata4 knockdown in both 
promoter constructs (Figure 3B). These data suggest that the effect of Gata4 knockdown on 
Scn5a mRNA levels in Figure 2A is the result of a promoter-dependent activity, although we 
cannot completely exclude the possibility that Gata4 siRNAs could have other indirect 
effects. 
 
We also tested whether the regulatory roles of GATA4 and GATA5 on the SCN5A promoter 
were dependent on the presence of specific GATA-BS. For this purpose, we generated two 
new versions of PromoterB-luciferase construct containing mutations in one or two predicted 
GATA-BS (Figure 3C and Supplementary Figure S1B). These predicted elements, located 
within the intron 1 region, are highly conserved among mammals (Supplementary Figure 
S5). Luciferase assays showed that activation of the SCN5A promoter by GATA4 decreased 
with the number of mutated GATA-BS. Similarly, GATA4 and GATA5 synergism was 
significantly reduced in GATA-BS mutant constructs (Figure 3C). These findings further 
support that GATA4 and GATA5 mediate their regulatory actions on SCN5A transcription via 
GATA-BS. However, those sites present in intron 1 would not be completely indispensable, 
since transcriptional activity of a promoter construct without these sites (PromoterA) is also 
increased upon GATA TFs overexpression (Figures 2B and 2C). 
 
Since GATA4 and GATA5 co-regulate the SCN5A promoter, we also tested whether GATA4 
and GATA5 interact. We transfected HEK293 cells with HA-tagged GATA4 and GATA5 
expression vectors and immunoprecipitated GATA4 from the lysates using anti-HA 
antibodies. GATA5 was detected in the immunoprecipitated material by Western blot, 
suggesting that GATA4 and GATA5 interact, directly or indirectly (Figure 3D). Collectively, 
our data suggest that GATA4 and GATA5 form a complex and synergistically activate 
SCN5A transcription via GATA-BS, including, but not exclusively, the most conserved 
GATA-BS in intron 1. 
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Figure 3. GATA4/GATA5 synergism is decreased in mutated intron 1 GATA-BS. A. Luciferase 
assays in H9c2 cells transiently transfected with PromoterA-luciferase or PromoterB-luciferase (200 
ng) and EF1αPromoter-Renilla (20 ng). Luciferase values were normalized with renilla (mean ± SEM, 
n=5). Significance was examined by the t-test. B. Luciferase experiments in H9c2 cells transfected 
with PromoterA-luciferase or PromoterB-luciferase, and control or Gata4 siRNAs. Luciferase values 
were normalized with renilla and are shown as percentage over control (mean ± SEM, n=3). 
Significance was examined by the t-test relative to control siRNA. C. Top. Schematic representation 
of the single and double mutant PromoterB constructs. The numbers indicate the initial and the end 
position from the TSS (represented by an arrow) and the black lines indicate the mutated GATA-BS. 
Nucleotide changes for GATA-BS1 and GATA-BS2 and their genomic position according to GRCh37 
©2017, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
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are also shown. Bottom. Luciferase experiments in H9c2 cells transfected with PromoterB-luciferase 
WT or mutated constructs and the indicated GATA factor expression vectors. Luciferase values were 
normalized with renilla and are shown as fold induction relative to control (mean ± SEM, n=3). 
Significance was examined by the t-test assay relative to the WT construct. D. Total lysates from 
HEK293 cells transfected with GATA4-HA and GATA5 expression vectors were immunoprecipitated 
with α-HA antibody. Western blot of input and immunoprecipitated samples is shown. Images are 
representative of two independent experiments. *p≤0.05, **p≤0.01, and ***p≤0.001. 
	
	
3.4. Correlation of GATA4 and SCN5A mRNA levels in Human Adult Heart 
 
To examine whether changes in SCN5A RNA directly correlate with sodium currents, we 
took advantage of Xenopus oocytes, which lack endogenous SCN5A and are a common 
model system in electrophysiological studies [23]. We injected increasing amounts of 
synthetic complementary RNA (cRNA) encoding human SCN5A in Xenopus oocytes and 
measured the corresponding NaV1.5 current using whole cell patch-clamp. We observed a 
positive and linear correlation between peak NaV1.5 current and injected levels of SCN5A 
cRNA (r2=0.9962; Figure 4A). Thus, the relative levels of SCN5A mRNA may have direct, 
linear biological effects.  
To investigate a direct relationship between levels of SCN5A mRNA and GATA TFs in 
human heart tissue, we next applied the high sensitive and accurate droplet digital (ddPCR) 
approach. In fresh-frozen left ventricle samples (four samples from healthy donors and 
fourteen samples from end-stage heart failure patients), we detected robust GATA4, GATA6, 
and SCN5A mRNA expression, as well as marginal but still clear signal over background for 
GATA5 mRNA (relative levels were as follows: GATA4 levels were 76-fold higher than 
GATA5 levels, and GATA6 levels were 2.6-fold higher than GATA4 levels; Figure 4B). 
Similarly, we detected the three GATA TFs by Western blot in a fresh-frozen human left 
ventricle sample (Supplementary Figure S6), although an accurate measurement of relative 
expression was not possible since each antibody intrinsically displays a particular affinity for 
its antigen.  
Notably, we observed a positive and significant (Pearson coefficient 0.63) correlation 
between GATA4 and SCN5A transcripts in human adult cardiac tissue (Figure 4B). No 
significant correlation was detected between GATA5 or GATA6 and SCN5A mRNA levels, or 
among GATA TFs (Figure 4B). Altogether, these results further support that GATA4 plays a 
major role in the regulation of SCN5A mRNA levels in human adult heart. 
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Figure 4. A. Left. Peak NaV1.5 current measurements of Xenopus oocytes injected with the indicated 
SCN5A cRNA concentrations. Numbers mean the measurements done in each condition. Right. 
Representative whole cell sodium current traces recorded from Xenopus oocytes injected with 1 and 
20 ng/µl of SCN5A cRNA. B. Droplet digital PCR analysis of GATA TF and SCN5A mRNA levels in 
n=18 human left ventricle samples. Data are displayed in scatter plots to compare each GATA TF with 
SCN5A mRNA levels, and Pearson correlation analysis was performed to determine statistical 
significant correlation. *p≤0.05, **p≤0.01, and ***p≤0.001. 
 
 
4. Discussion 
 
This study reveals that GATA4 synergizes with GATA5 in the activation of the SCN5A gene 
via binding to GATA-BS within the SCN5A proximal promoter and intron 1 regions. This 
conclusion is supported by experiments performed in human adult left ventricle tissue, as 
well as in a cell line derived from rat embryonic ventricle. Our ddPCR analysis also reveals a 
positive and significant correlation between GATA4 (but not GATA5 or GATA6) and SCN5A 
mRNA levels in human cardiac samples, thus supporting a direct role of GATA4 in regulating 
SCN5A gene expression in the human heart. We should note, however, the limitation of this 
ddPCR analysis, since heart samples included the three heart layers (epicardium, 
myocardium and endocardium). Thus, the relative abundance of each layer in each sample 
may affect the overall measured levels of GATA factors and SCN5A, since SCN5A 
expression has been reported to vary across the human cardiac ventricular wall [24]. 
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Previous reports showed synergistic effects of GATA4 with other TFs, including GATA6 [20], 
Nkx2-5 [25], TBX5 [16], and MEF2 [26]. Consistent with these effects, recent ChIP-seq 
studies in mouse cardiomyocytes identified cardiac enhancers co-occupied by multiple TFs, 
including GATA4 [27-29]. Notably, GATA4 was shown to co-locate with TBX3, TBX5, and 
NKX2-5 on two enhancers, included within the mouse Scn10A gene and downstream of the 
Scn5a gene [6, 30]. These two enhancers activate Scn5a transcription by looping with the 
Scn5a promoter, as it was shown by 4C-seq [7]. Here, therefore, we favor a mechanism by 
which GATA4 may function with GATA5 and other TFs, yet to be determined, to regulate the 
SCN5A gene. Although the role of GATA5 in the human adult heart remains unclear [10, 11, 
31-34], our results favor a model in which GATA4 and GATA5 co-regulate the SCN5A gene, 
and we speculate that part of the controversy about GATA5 expression in the adult heart can 
be explained by divergent mRNA and protein GATA5 levels. 
 
Our ChIP and Re-ChIP experiments suggest that GATA4 and GATA5 bind to the SCN5A 
promoter and intron 1 regions in the human adult heart, while no binding is detected in far 
upstream regions (-8803 bp and from -5916 bp). These observations are in agreement with 
recent findings showing that, in mouse fetal heart, ~80% of GATA4 sites are distal to TSS 
regions; however, in mouse adult heart, GATA4 shifts to TSS-proximal locations, and only 
~45% of GATA4 sites are distally located [13]. In this study, He et al. detected GATA4 ChIP-
seq signal at the mouse Scn5a promoter, but not at intron 1 [13]. Data from the Mouse 
ENCODE Project revealed that cis-regulatory elements have undergone important 
evolutionary changes between human and mouse, but the regulatory networks are highly 
conserved between orthologous cell types of both species [35]. Consistently, we speculate 
that, although GATA4-BS differ between human and mouse, GATA4 function as regulator of 
SCN5A gene is preserved. This possibility is supported by the observation of substantial 
reduction in H3K27 acetylation, a histone mark associated with active transcription, on the 
Scn5a promoter in Gata4 knockout mouse embryos, thus confirming the importance of 
GATA4 in SCN5A gene expression activation [13].    
The identification of GATA4 and GATA5 as novel regulators of SCN5A transcription raises 
the possibility that these factors may be associated with arrhythmogenic diseases. Genetic 
variants in GATA4 (or GATA5) genes could be related to arrhythmogenic diseases via 
dysregulation of SCN5A expression. The effect of mutations on GATA4 (and GATA5) 
function could determine the levels of NaV1.5 channel expression, which could explain the 
variability of phenotypes associated with SCN5A-related arrhythmias. In support of this idea, 
Gata4 +/- mice, although viable, display short PR intervals [14]. 
Our data also raises the intriguing question whether genetic variation in GATA-BS could lead 
to arrhythmogenic diseases. Single nucleotide variants (SNVs), insertions, and deletions 
affecting GATA-BS could impair GATA TF regulatory functions on the SCN5A gene, thereby 
modulating SCN5A expression or even protecting from cardiac arrhythmias. The 1000 
Genomes database includes two SNVs in the GATA-BS regions studied here, rs552565807 
and rs115996915, but direct studies would be needed to identify their potential effects in 
SCN5A expression. In any case, the possibility that genetic variations in GATA-BS could 
lead to arrhythmias is already supported by genome-wide association (GWAS) studies 
indicating that most disease-associated variants lie within regulatory regions [36]. Indeed, de 
novo discovery of mutations in nonexonic regions (versus exonic regions) holds the promise 
that uncovering the transcriptional regulation of cardiac genes can lead to a better 
understanding of heart diseases.  
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5. Conclusions 
 
In this study, we report the regulatory role of GATA4 on the SCN5A gene in human heart. 
Our work provides evidences that: 1) GATA4 and GATA5 co-occupy the SCN5A promoter 
and the first intronic regions, interact, and synergize to regulate the expression of the 
SCN5A gene in human heart tissue; 2) two GATA-BS found in intron 1 are important but not 
the sole contributor elements for this regulatory role; and, 3) GATA4 and SCN5A mRNA 
levels positively correlate in adult human hearts. Overall, we anticipate that the study of 
NaV1.5-related arrhythmias will need to extend to GATA TFs and GATA-BS. 
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